Last reviewed · How we verify
F-ARAG
At a glance
| Generic name | F-ARAG |
|---|---|
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors (PHASE2)
- Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of COVID-19 (PASC) (EARLY_PHASE1)
- Detection of Graft Versus Host Disease With [18F]F-AraG (PHASE1)
- 18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer (PHASE1)
- Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC (PHASE1, PHASE2)
- [18F]F-AraG/Total Body PET Imaging and Healthy Subjects and Lung Cancer Patients (EARLY_PHASE1)
- Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer (NA)
- [18F]F-AraG PET Imaging to Visualize Tumor Infiltrating T-cell Activation in Non-small Cell Lung Cancer. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- F-ARAG CI brief — competitive landscape report
- F-ARAG updates RSS · CI watch RSS